Eli Lil­ly ends Q1 on a high note on the heels of pos­i­tive obe­si­ty tri­al da­ta

It was all about tirzepatide for Eli Lil­ly this morn­ing. And in the im­me­di­ate af­ter­math of a Phase III read­out, an­a­lysts want­ed to know what the phar­ma has planned next.

Lil­ly an­nounced on Thurs­day morn­ing that Q1 num­bers are in, and rev­enue grew by just un­der 15%. Much of the fo­cus, how­ev­er, was on tirzepatide, an ex­per­i­men­tal GIP and GLP-1 re­cep­tor ag­o­nist made up of a sin­gle pep­tide, for obe­si­ty. No­vo Nordisk orig­i­nal­ly chal­lenged Lil­ly last year af­ter show­ing that its di­a­betes drug We­govy, re­spon­si­ble for more than a bil­lion dol­lars in sales, was ef­fec­tive at treat­ing non-di­a­bet­ic adults with obe­si­ty.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER